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mechanisms of chronic pancreatitis. We investigated the roles
of complement component 5 (C5) in pancreatic ﬁbrogenesis in
mice and patients. METHODS: Chronic pancreatitis was
induced by ligation of the midpancreatic duct, followed by a
single supramaximal intraperitoneal injection of cerulein, in
C57Bl6 (control) and C5-deﬁcient mice. Some mice were given
injections of 2 different antagonists of the receptor for C5a over
21 days. In a separate model, mice were given injections of
cerulein for 10 weeks to induce chronic pancreatitis. Direct
effects of C5 were studied in cultured primary cells. We per-
formed genotype analysis for the single-nucleotide poly-
morphisms rs 17611 and rs 2300929 in C5 in patients with
pancreatitis and healthy individuals (controls). Blood cells from
976 subjects were analyzed by transcriptional proﬁling.
RESULTS: During the initial phase of pancreatitis, levels of
pancreatic damage were similar between C5-deﬁcient and
control mice. During later stages of pancreatitis, C5-deﬁcient
mice and mice given injections of C5a-receptor antagonists
developed signiﬁcantly less pancreatic ﬁbrosis than control
mice. Primary pancreatic stellate cells were activated in vitro
by C5a. There were no differences in the rs 2300929 SNP be-
tween subjects with or without pancreatitis, but the minor
allele rs17611 was associated with a signiﬁcant increase in
levels of C5 in whole blood. CONCLUSIONS: In mice, loss of C5
or injection of a C5a-receptor antagonist signiﬁcantly reduced
the level of ﬁbrosis of chronic pancreatitis, but this was not a
consequence of milder disease in early stages of pancreatitis.
C5 might be a therapeutic target for chronic pancreatitis.*Authors share co-ﬁrst authorship; §Authors share co-senior authorship.
Abbreviations used in this paper: C5, complement component 5; HSC,
hepatic stellate cell; IL, interleukin; IP, intraperitoneal; MPO, myeloper-
oxidase; PSC, pancreatic stellate cell; aSMA, a smooth muscle actin; SNP,Keywords: Pancreatic Stellate Cells; Transcriptome Analysis;
Complement System; aSMA.
hronic pancreatitis is an inﬂammatory disease of thesingle-nucleotide polymorphism; TGFb, transforming growth factor b;
TNFa, tumor necrosis factor a.
Most current article
© 2015 by the AGA Institute
0016-5085
http://dx.doi.org/10.1053/j.gastro.2015.05.012
Open access under CC BY-NC-ND license.Cpancreas. Periodic repetitive inﬂammatory events
result in the replacement of exocrine and endocrine tissue
by ﬁbrotic or fatty tissue, which leads to the loss of
pancreatic function.1,2
The activation of pancreatic stellate cells (PSCs) is crit-
ical for the formation of extracellular matrix and ﬁbrosis.3PSCs are present in their quiescent phenotype in the
healthy pancreas, but during pancreatic injury and inﬂam-
mation they undergo activation. Major activators of PSCs
include inﬂammatory mediators such as transforming
growth factor b (TGFb), tumor necrosis factor a (TNFa), or
interleukin (IL)6,4,5 as well as ethanol and its metabolites.6
Stellate cells respond to these activators with an increased
expression of a smooth muscle actin (aSMA); an excessive
release of extracellular matrix proteins such as collagen type
I, III, or ﬁbronectin; and increased cell proliferation.5,7 He-
patic stellate cells (HSCs), which are related closely to PSCs,8
have a similar activator proﬁle.9
Preliminary data have suggested a critical role of com-
plement factor 5 (C5) in liver ﬁbrosis. Mice deleted in C5
show signiﬁcantly reduced liver ﬁbrosis upon CCl4 treat-
ment and the same phenotype was achieved by treatment
with a C5a-receptor antagonist.10 In mice, mutations of C5
have been associated with liver ﬁbrosis, and 2 single-
nucleotide polymorphisms (SNPs) in human C5 have been
reported to increase the risk of ﬁbrosis in patients with
hepatitis C.10,11 The biological role of C5 mutations are
discussed controversially because a second larger study
could not reproduce the initial association.12 However, C5
mutations have not yet been studied in the context of
chronic pancreatitis.
C5a is a cleavage product of C5, which is generated
during the classic and the alternative pathways of comple-
ment activation. C5a is a potent chemoattractant for neu-
trophils and macrophages and directly acts on a number of
parenchymal cells via binding to the C5a receptor (CD88).
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PANCREASDuring pancreatitis the complement system undergoes
activation and serum levels of anaphylatoxin (C5a) correlate
with the severity of the disease.13,14 Pancreatitis is charac-
terized by premature activation of zymogenes within the
acinar cells, which leads to autodigestion of the organ,
resulting in a systemic inﬂammatory response. A crucial
step in the activation cascade leading to autodigestion is the
activation of trypsinogen by cathepsin B.15 Trypsin is also a
potent complement activator cleaving C3 and C5, which
results in the release of C3a and C5a, the enzymatically
active form.16 These 2 aspects, the activation of C5 by
trypsin during pancreatitis and the potential impact of C5a
on ﬁbrogenesis, suggest a critical role of C5a in the pro-
gression of chronic pancreatitis.
The aim of this study was to study chronic pancreatitis
in 2 animal models mimicking the human disease and to
investigate the role of C5 in the development of ﬁbrosis and
its potential as a therapeutic target. We also studied the
effect of disease-relevant SNP genotypes and their associa-
tion with the transcriptome in whole blood.Figure 1. Characterization of combined duct ligation and supra
atitis in mice. Chronic pancreatitis was studied in C57BL6 m
secretagogue stimulation. In the mouse pancreas the common
and the side branches from the pancreatic head drain into the bi
pancreatic duct at the junction between the duodenal, splenic, a
reduced amylase staining in the pancreas 14 days after duct lig
part of the pancreas, (D) some stellate cells show a positive o
peaked at day 3. Loss of exocrine tissue was observed only in
measured as fecal elastase activity was preserved. Quantiﬁcatio
staining showed a necrosis-ﬁbrosis sequence (n ¼ 5–8).Materials and Methods
See the Supplementary Materials and Methods section for
more detail. In brief, C57Bl6 mice were purchased from Charles
River (Sulzfeld, Germany), breeder pairs of C5-deﬁcient mice as
well as C5 wild-type animals were purchased from Jackson Lab
(Bar Harbor, Maine).17 Chronic pancreatitis was induced by
ligation of the pancreatic duct at the junction between the
gastric and the duodenal lobe, sparing the bile duct and its
concomitant artery in animals at the age of 8–10 weeks,
weighing approximately 25 g (Figure 1A). The animals received
a single intraperitoneal (IP) injection of cerulein (50 mg/kg/
body weight) 2 days after duct ligation. Animals were killed 3,
7, 14, and 21 days after ligation. Inhibition of C5a receptor was
performed by daily IP injections of C5a-receptor antagonist W-
54011 (200 mg/kg/body weight; Calbiochem, San Diego, CA18)
starting 4 days after duct ligation. The peptide inhibitor AcF-
(OpdChaWR) as well as its inactive control peptide Acd-
ChaPWFRO-NH2 were synthesized by Biosyntan GmbH (Berlin,
Germany) and injected daily intraperitoneally at a concentra-
tion of 10 mmol/L starting at day 4 after ligation.19 Animals
were killed 14 days after pancreatic duct ligation. As a secondmaximal secretagogue stimulation to induce chronic pancre-
ice using a combination of duct ligation and supramaximal
bile duct passes through the duodenal lobe of the pancreas
le duct before reaching the papilla. (A) We therefore ligated the
nd gastric lobe. (B) The loss of exocrine tissue was shown by
ation. (C) Fatty tissue replacement developed in the affected
il red staining in small fat droplets. (E) Serum amylase level
the disease-affected part, whereas overall exocrine function
n of necrosis on H&E staining and ﬁbrosis in Masson–Goldner
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weight) IP injections twice a week over a time period of 10
weeks. Animals were killed 2 days after the last course of in-
jection. All animal experiments were performed after prior
institutional review board approval. More than 5 animals were
used for each experiment and all experiments were performed
in triplicate. All experiments were performed independently on
3 or more occasions. Asterisks indicate signiﬁcant differences
with a P value less than .05 and can be found on top of the
graphs. The following antibodies were used for immunohisto-
chemistry as well as immunoﬂuorescence and were used as
previously described: collagen-I (cat no. ab292; Abcam, Cam-
bridge, United Kingdom), Ki67 (cat no. IHC-00375; Bethyl,
Montgomery, TX), aSMA (clone 1A4; Sigma-Aldrich,
Taufkirchen, Germany), anti–Mac-3 antibody (clone M3/84;
BD Pharmingen, Heidelberg, Germany), and anti-
myeloperoxidase (MPO) antibody (cat no. ab45977; Abcam,
Cambridge, United Kingdom). Anti-protein gene product 9.5
(ref. Z5116; Dako, Hamburg, Germany), anti-insulin (4590; Cell
Signaling, Leiden, The Netherlands), C5a receptor (CD88) (cat
no. 135804; BioLegend, San Diego, CA) for IF and CD88 (cat no
sc-25774; Santa Cruz Biotechnology, Dallas, TX) for IHC, CD68
(M1 macrophages), and CD206 (M2 macrophages) (antibody
online cat no. ABIN181836 and cat no ABIN1386219, Aachen,
Germany). Quantiﬁcation of Goldner staining and immunohis-
tochemistry was obtained using ImageJ software (National In-
stitutes of Health, Bethesda, MD) (Supplementary Figure 1). Oil
red staining was generated by the Oil-Red-O-Stain-Kit (IHC
World, Woodstock, MD) and by Masson–Goldner staining using
a kit from Merck (Darmstadt, Germany). Amylase, lipase con-
centrations, MPO, and Western blot of tissue or PSCs was per-
formed as previously described.20 Stellate cells were isolated
from murine pancreas as described by Apte et al.21 Blood
samples from patients with pancreatitis and blood donors at our
institution were collected after informed consent and ethics
committee approval.22 For SNP analysis only acute pancreatitis
of a nonbiliary and non–endoscopic retrograde chol-
angiopancreatography–induced etiology, and for chronic disease
only alcohol-induced or idiopathic pancreatitis, were included.
TaqMan assays C_11720402_10 for the SNP rs17611 and
C_2783669_1 for SNP rs2300929 was purchased from Life
Technologies (Grand Island, NY). TaqMan products were veri-
ﬁed by direct sequencing. The Study-of-Health-in-Pomerania is a
longitudinal population-based cohort study in Western Pomer-
ania.23 The presented expression of quantitative trait loci anal-
ysis is based on a subset of 976 subjects.Results
Ligation of the Gastric and Splenic Part of the
Pancreatic Duct in Combination With
Supramaximal Secretagogue Stimulation Leads
to Chronic Pancreatitis With Signiﬁcant Fibrosis
and Loss of Exocrine Tissue
Chronic pancreatitis is characterized by a necrosis-
ﬁbrosis sequence.24 The hallmark of the disease onset is
characterized by the necrosis of acinar tissue. During
pancreatic regeneration necrotic areas are replaced by
extracellular matrix, resulting in extensive ﬁbrosis. To study
chronic pancreatitis in mice we used 2 models: ﬁrst, using acombination of duct ligation and supramaximal cerulein (50
mg/kg/body weight) stimulation (Figure 1A), and, second,
repetitive supramaximal (50 mg/kg/body weight) cerulein
IP injections. To characterize the ﬁrst model we analyzed
pancreatic tissue on days 3, 7, 14, and 21 after surgery;
animals who received only ligation of the pancreatic duct
(Supplementary Figure 2A) as well as sham-operated ani-
mals served as controls (0 days). Ligation of the pancreatic
duct followed by a single cerulein injection 2 days after
surgery resulted in severe necrotizing pancreatitis in the
ligated part of the pancreas, whereas the nonligated part
was not affected 3 days after surgery (Figure 1A). Model-
associated mortality ranged from 10% to 15% and always
occurred within 48 hours of cerulein injection. Affected
animals died from severe necrotizing pancreatitis and sub-
sequent organ failure. Pancreatic necrosis was replaced by
ﬁbrotic tissue and maximal ﬁbrosis was detected after 21
days (Figure 1A), as shown by the quantiﬁcation of necrosis
and ﬁbrosis on histology (Figure 1B and E). Compared with
the chronic pancreatitis model using repetitive cerulein in-
jections over 10 weeks, the combination of duct ligation
with a single cerulein injection lead to a signiﬁcantly
enhanced ﬁbrosis reaction (Supplementary Figure 3A and
B). In addition to the development of ﬁbrosis, fatty tissue
replacement in the pancreas was observed in the ligation
model (Figure 1C). Oil red staining showed not only fatty
tissue replacement, but also a signiﬁcant number of PSC
cells with small intracellular lipid droplets at 21 days after
ligation (Figure 1D). Serum amylase (Figure 1E) as a marker
for local pancreatic damage was increased signiﬁcantly on
day 3, but returned to normal on days 7, 14, and 21 after
ligation (Figure 1E). The model reported here is character-
ized by a loss of digestive enzymes in the affected part of the
pancreas (Figure 1E) and by a necrosis-ﬁbrosis sequence
(Figure 1E). Because only half of the pancreas is affected,
animals do not develop overt exocrine (Figure 1E) or
endocrine insufﬁciency (Supplementary Figure 4C).
To obtain a more detailed characterization of the mouse
model a number of histologic stainings were performed.
H&E staining illustrated the altered pancreatic morphology
with initially large areas of necrosis and a pronounced in-
ﬂammatory inﬁltrate. Over time, this was replaced by
ﬁbrotic tissue, degeneration of pancreatic acini, and a slowly
decreasing inﬂammatory inﬁltrate resulting ﬁnally in scar
tissue (Figure 2). Masson–Goldner trichrome staining
allowed visualization of the extent of ﬁbrogenesis (green) in
the pancreas and the concomitant loss of exocrine tissue
(red) over time in the ligated part of the pancreas (Figure 2).
Immunohistochemical staining of the extracellular matrix
proteins collagen-I and aSMA in pancreatic tissue indicated
a similar trend by day 7, reaching its maximum 21 days
after ligation (Figure 2). aSMA staining points to the acti-
vation of stellate cells, which is known to play a crucial role
for pancreatic regeneration, ﬁbrosis, and the production of
extracellular matrix.25 Ki67, a marker of proliferation, was
detected mainly in inﬂammatory cells in the early disease
phase but later also in the nuclei of acinar cells during organ
regeneration (Figure 2). The acute phase of pancreatitis in
this model was characterized by a massive inﬁltration of
Figure 2.Morphologic
characterization of the duct
ligation model of chronic
pancreatitis. The histologic
characterization of pancre-
atic specimens in the duct
ligation model of chronic
pancreatitis showed typical
features of chronic pan-
creatitis. H&E as well as
Masson–Goldner staining
showed a large increase
in ﬁbrosis. Immunohisto-
chemical staining of col-
lagen I and aSMA showed
activation of PSCs and
increased ﬁbrogenesis with
production of extracellular
matrix proteins at 14 and
21 days after duct ligation.
Pancreatic regeneration is
marked by proliferating
Ki67-positive acinar cells
and tubular complexes 14
and 21 days after surgery.
The transmigration of the
innate immune cells was
shown by Mac-3 staining
for macrophages and MPO
staining for neutrophils.
Enlarged neural structures
also were a common
aspect of chronic pan-
creatitis, labeled here with
protein gene product 9.5,
suggesting neural sprout-
ing. Insulin staining showed
intact b-cells in islands of
Langerhans (n ¼ 5–8).
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duct ligation macrophages as indicated by anti–Mac-3
staining (Figure 2) and neutrophils labeled with a MPO
antibody (Figure 2) were found to transmigrate. Although
initially the M1 population of macrophages was more
prominent in the course of chronic pancreatitis, M2 mac-
rophages prevailed at later time points (Supplementary
Figure 4D). The systemic immune reaction was conﬁrmed
by increased serum IL6 levels and lung histology(Supplementary Figure 4A and B). In the chronic phase we
detected nerve sprouting as another characteristic feature of
chronic pancreatitis and the inﬁltration of immune cells
toward these nerves that are thought to mediate neuro-
pathic pain,26 together with an increased nerve diameter in
later stages of the disease as shown by protein gene product
9.5 (PGP 9.5) labeling (Figure 2).Open-ﬁeld analysis of the
animals to measure pancreatic pain conﬁrmed this ﬁnding.
Voluntary movement and the distance traveled by animals
September 2015 C5 Mediates Fibrosis in Chronic Pancreatitis 769in the duct-ligation model was decreased signiﬁcantly in
comparison with controls and animals after repetitive cer-
ulein injections (Supplementary Figure 2B).Chronic Pancreatitis in C5-Deleted Mice
We used the same 2 models (ligation with a single cer-
ulein injection and repetitive IP cerulein) in C5-deﬁcientFigure 3. Course of chronic pancreatitis and extent of ﬁbrogen
systemic inﬂammatory reaction after induction of pancreatitis w
Inﬂammation was conﬁrmed by H&E staining of the lung. (B) The
strains. H&E staining of pancreatic tissue showed severe acute
of pancreatitis. Twenty-one days after surgery necrotic areas w
imals. (C) The quantiﬁcation of ﬁbrosis showed a signiﬁcant diff
mice. (D) The expression of aSMA in the pancreas was reduced
labeling for the extracellular matrix protein collagen I as well as
compared with C5þ/þ mice (n ¼ 5–10). Asterisks indicate sign(C5-/-) animals and their respective wild-type littermates
(C5þ/þ).
Initially, we studied the systemic inﬂammation
because C5 is a potent chemoattractant. MPO activity in
lung tissue did not differ between the 2 animal strains,
however, C5-deﬁcient mice appeared to recruit higher
numbers of neutrophils to the lungs (Figure 3A), but this
trend did not reach statistical signiﬁcance (Figure 3B). Toesis in C5-/- and C5þ/þ in the duct ligation model. (A) The
as illustrated by MPO activity measurements in lung tissue.
re was no difference in serum amylase levels between animal
pancreatitis with large areas of necrosis 3 days after induction
ere replaced by ﬁbrotic tissue in C5þ/þ but not in C5-/- an-
erence with regard to ﬁbrogenesis between C5þ/þ and C5-/-
in C5-/- animals after 21 days. (E and F) In the more speciﬁc
aSMA C5-/- animals showed a less pronounced expression
iﬁcant differences with P < .05.
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Figure 4. Extent of ﬁbro-
genesis in the course of
chronic pancreatitis in
C5-/- and C5þ/þ animals
in the model of repetitive
cerulein stimulation. Mas-
son–Goldner staining of
pancreatic tissue was
analyzed by ImageJ soft-
ware (National Institutes of
Health). (A–C) C5-deleted
animals showed signiﬁ-
cantly less ﬁbrosis in
Masson–Goldner staining
as well as aSMA and
collagen I expression. (D)
The percentage of Ki67-
positive cells was reduced
signiﬁcantly in C5-/- ani-
mals, whereas (E) serum
amylase and lipase activity
were unaffected by C5
deletion (n ¼ 5–7). Aster-
isks indicate signiﬁcant
differences with P < .05.
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in the initial phase, which might reﬂect on the chron-
iﬁcation, we measured serum amylase concentrations at
day 3 as well as 21 days after the onset of pancreatitis
(Figure 3B). Both animal strains showed a signiﬁcant in-
crease in serum amylase activity but no differences were
detected between the groups. Twenty-one days after in-
duction of pancreatitis the serum amylase levels had
decreased back to near baseline levels. Histology of the
pancreas showed extensive necrotic areas in both animal
strains (Figure 3B), which was replaced by ﬁbrotic tissue
in C5þ/þ but not in C5-/- mice after 21 days. In both
experimental models there was no difference in acute
severity or initial necrosis between C5-deleted and wild-
type animals (Supplementary Figure 5A–D). There was
no difference in serum amylase or lipase activity, or for
the inﬁltration of neutrophils as shown by pancreatic MPO
activity between C5-/- and C5þ/þ animals. The deletion
of C5 did not affect severity or immune response during
the early disease phase, conﬁrming previous observations
by Bhatia et al.27
Quantiﬁcation of pancreatic ﬁbrosis was performed
by Masson–Goldner staining and immunohistochemistry
was performed for collagen I and aSMA. All markers
evaluated showed a signiﬁcant reduction of ﬁbrotic tis-
sue in the C5-deleted animals (Figure 3C–F) in the liga-
tion/cerulein injection model and were conﬁrmed in the
repetitive cerulein (10 weeks) injection model
(Figure 4A–D). Again, markers for disease severity during
the initial acute phase did not differ between the mouse
strains (Figure 4E).
The observation that the absence of ﬁbrosis in C5-
deleted animals was independent of the differences in
initial disease severity between C5þ/þ and C5-/- mice(which was indistinguishable) suggests that C5 plays a
direct role in ﬁbrogenesis.
C5a Activates Pancreatic Stellate Cells
In resection specimens from chronic pancreatitis tissue of
mouse and human pancreas we stained CD88-positive cells
within the ﬁbrotic tissue (Figure 5A and B) and conﬁrmed the
expression of CD88 on Western blot (Figure 5B). Further-
more, in murine pancreatic tissue we identiﬁed cells
expressing aSMA and the C5a receptor (Figure 6A), sug-
gesting that PSCs express the C5a receptor on their surface.
By reverse-transcription polymerase chain reaction and on
Western blot analysis we detected the expression of CD88 on
freshly isolated PSCs in vitro (Figure 6B and C). Stimulation of
PSCs with recombinant mouse C5a for 72 hours lead to sig-
niﬁcant up-regulation of aSMA expression. Stimulation with
TGFb as well as incubation with a C5a-receptor-1 inhibitor
served as controls (Figure 6C and D). Real-time polymerase
chain reaction analysis conﬁrmed these ﬁndings and showed
up-regulation of extracellular matrix proteins such as ﬁbro-
nectin, as well as aSMA (Figure 6E). PSCs of C5-/- mice
showed no functional defects and responded in the same
manner to TGFb and C5a (data not shown). These experi-
ments indicated a direct effect of C5a on PSC trans-
differentiation to an activated, myoﬁbroblast-like phenotype
that synthesizes and secretes extensive amounts of extra-
cellular matrix proteins.3,28
Inhibition of the C5a-Receptor-1 Protects
Against the Development of Fibrosis in the Duct
Ligation Model of Chronic Pancreatitis
Anti-C5 treatment of chronic pancreatitis was achieved
by using 2 different inhibitors of the C5a-receptor-1 (CD88):
September 2015 C5 Mediates Fibrosis in Chronic Pancreatitis 771a small-molecule inhibitor (C5a-receptor antagonist) and a
peptide inhibitor. Both inhibitors were used in a therapeutic
approach starting 4 days after duct ligation. All markers of
ﬁbrosis (trichrome, collagen I, and aSMA) were reduced
signiﬁcantly by the C5a-receptor antagonist treatment
compared with untreated pancreatitis animals. The peptide
inhibitor directed against the C5a-receptor-1 was less
effective compared with the small-molecule inhibitor, but
also resulted in a trend toward reduced ﬁbrosis
(Figure 7A–C).C5 SNPs Are Not Associated With an Increased
Risk of Chronic Pancreatitis in Human Beings But
With C5 Expression in a Population-Based
Setting
Two common genetic polymorphisms have been
described previously to be associated with an increased
risk for developing liver ﬁbrosis.10,11 We therefore inves-
tigated whether these putative risk alleles, rs17611_A and
rs2300929_T, are associated signiﬁcantly with chronic
pancreatitis. We genotyped these 2 SNPs in 390 chronic
pancreatitis patients, 133 patients with acute pancreatitis,
and 384 healthy blood donors and compared allele fre-
quencies. No signiﬁcant differences could be found be-
tween the groups (Supplementary Table 1), indicating that
the 2 analyzed SNPs may not confer an individual risk forFigure 5. C5a-receptor
expression on pancreatic
stellate cells in chronic
pancreatitis. (A and B) On
immunoﬂuorescence and
Western blot analysis PSCs
expressed CD88, the re-
ceptor of C5a as well as
aSMAinpancreatic tissueof
animals with chronic
pancreatitis. Fluorescence
staining indicated expres-
sion of CD88 on pancreatic
stellate cells as well as on
immune cells. (C) Human
tissue samples of chronic
pancreatitis patients
showed a strong signal
for aSMA and C5a (CD88)
(n ¼ 5–7). GAPDH, gly-
ceraldehyde-3-phosphate
dehydrogenase.the development of chronic pancreatitis in patients with
similar risk proﬁles. Patient characteristics are shown in
Supplementary Table 2. However, a cis-expression of
quantitative trait loci analysis of 976 volunteers from the
Study of Health in Pomerania–Trend cohort showed a sig-
niﬁcant association of rs17611_A with increased C5
expression in whole blood (P ¼ 6.87  10-41 after adjust-
ment for the ﬁrst 50 principal components)
(Supplementary Figure 6A). This indicates a correlation
between C5-genotype and C5-protein expression. To show
an association between C5 genotype variants and the risk
of pancreatitis may require a much larger multicenter pa-
tient cohort.Discussion
Chronic pancreatitis is burdened not only with a signif-
icant reduction in the quality of life of affected patients and
an excess mortality, but also considerable health care costs.1
Pancreatic ﬁbrosis is a hallmark of the disease, but because
of a lack of appropriate in vitro and in vivo models and
because repeated tissue samples from patients are not
available the underlying pathophysiological mechanisms of
disease progression are poorly understood. Even in the 21st
century we cannot offer a causal treatment to our patients
or one that alters the natural history of pancreatic ﬁbrosis. It
is still unclear how ﬁbrogenesis is initiated in the inﬂamedBA
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Figure 6. C5a activates PSCs in vitro, which leads to extracellular matrix deposition. Pancreatic stellate cells were isolated
from C57Bl6 mice. (A) The expression of C5a receptor (CD88) on stellate cells was analyzed by immunoﬂuorescence staining
of isolated PSCs. (B and C) Reverse-transcription polymerase chain reaction as well as immunoblotting of PSC lysates
conﬁrmed positive immunoﬂuorescence staining. (C) Proliferation shown by proliferating cell nuclear antigen (PCNA) Western
blot was not affected by C5a stimulation. Murine PSCs express the C5a receptor and respond to recombinant mouse C5a with
up-regulation of aSMA. (D) Four independent experiments were analyzed by Western blot and the ratio of aSMA/glyceral-
dehyde-3-phosphate dehydrogenase (GAPDH) optical density (OD) was calculated. (E) PSCs treated with C5a showed
up-regulation of aSMA and ﬁbronectin messenger RNA (mRNA) on real-time polymerase chain reaction analysis. TGFb-
stimulated and untreated cells acted as controls, a C5a-receptor antagonist was used to block stimulation (n ¼ 4).
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are warranted. Currently, there are 2 pathophysiological
concepts: the ﬁrst of these is based on the inﬂammation-
necrosis-ﬁbrosis sequence as the underlying pathogenicmechanism,25,29 and the second concept focuses on the
direct activation of pancreatic stellate cells via a pathologic
stimulus.30 In the ﬁrst scenario the initial lesion starting the
sequence is autodigestion by prematurely activated
Figure 7. Treatment with C5a inhibitors attenuates ﬁbrosis in the duct ligation model. Treatment with C5a-receptor antagonist
and a peptide inhibitor of C5a was initiated 4 days after duct ligation and effects on ﬁbrosis were evaluated after 14 days. (A
and B) Both treatments lead to a signiﬁcant reduction of Masson–Goldner, collagen I, and aSMA staining on histologic
evaluation. (C) Western blot analysis for aSMA from pancreatic lysates conﬁrmed this ﬁnding for the C5a-receptor antagonist
and showed a similar trend that was not statistically signiﬁcant for the peptide inhibitor (n ¼ 6–9).
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established an animal model in which protease activation,
systemic inﬂammation, and acinar cell necrosis are the
starting points of chronic pancreatitis and in which we can
show that the proinﬂammatory cytokine C5, most likely
activated via proteolytic cleavage by pancreatic proteases,
directly acts on PSCs and thus promotes ﬁbrogenesis.
Repetitive cerulein application twice weekly over a
period of 10 weeks, the model used here as pancreatitis
control, is the most widely used model of chronic pancre-
atitis in mice.31 It causes collagen deposition, which re-
gresses when injections are discontinued. Combined
lipopolysaccharide and ethanol application, an established
rat model of chronic pancreatitis injury, has not been tested
in mice, and dibutyl-tin-chloride is unsuited for experi-
ments in mice because of differences in pancreatic and bile
duct anatomy between rodents.32 The model developed andcharacterized in this study includes a number of charac-
teristic features observed in human disease and thus shows
advantages over previous models: (1) progressive tissue
destruction, activation of stellate cells, and exocrine tissue
replacement by extracellular matrix after a single injury;
(2) duct dilatation and duct plugging; (3) a strong inﬂam-
matory reaction and tissue regeneration; and (4) nerve
sprouting combined with marked pancreatic pain. Howev-
er, by design, the model only affects part of the pancreas,
which has the advantage that each animal can serve as its
own histologic control and that exocrine and endocrine
function are preserved, therefore allowing long-term
studies. Furthermore, this model offers the opportunity to
use different genetically engineered mice in a highly
reproducible setting.
To study ﬁbrogenesis in chronic pancreatitis we inves-
tigated the role of C5. Our study showed a direct effect of C5
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chronic pancreatitis.
The complement system represents a part of the innate
immune system, which is involved in bacterial defense and
attracts neutrophils and macrophages to the site of inﬂam-
mation. It is well established that activation of inﬂammatory
cells determines the severity of pancreatitis.33 To our sur-
prise, the deletion of C5 did not result in decreased
inﬂammation or a reduced severity of acute pancreatitis.
Reports in the literature on this aspect are controversial.
Although Merriam et al34 reported a less severe phenotype
of pancreatitis in C5-deﬁcient mice, Bhatia et al27 observed
an increase in severity with a more pronounced inﬂamma-
tory response in C5-deleted animals. In our setting we found
no effect of an inﬂuence of C5 deletion on the severity of
acute pancreatitis. A possible explanation for this ﬁnding
could be the compensation of C5a by other proinﬂammatory
cytokines or chemokines such as monocyte chemoattractant
protein-1, IL6, or TNFa.35,36
With regard to ﬁbrogenesis our data differed completely
and suggested that parenchymal necrosis is the initiator of
ﬁbrosis, and that the extent of ﬁbrogenesis is determined by
the presence of C5a. C5a was found to play an important
role in liver ﬁbrosis by stimulating HSCs.10 HSCs express the
C5a receptor on their surface and a direct activating effect of
C5a on HSCs has been reported.37,38 PSCs are related closely
to HSCs.8 PSCs are responsible for the production of extra-
cellular matrix proteins and tissue ﬁbrosis during chronic
pancreatitis. The activation of PSCs is mediated by a
plethora of different cytokines such as IL6, TNFa, TGF-b,
and IL10,4,7,39 and results in an increased expression of
aSMA. In addition to the activation of PSCs within the
pancreas, their progenitor cells migrate from bone marrow
into the pancreas. C5a appears to play a role as a direct
activator of PSCs as well as a chemokine for PSC progenitor
cells or the recruitment of inﬂammatory cells into the
pancreas and to promote ﬁbrosis. Our experiments show
that C5a can activate PSCs in vivo and in vitro. This suggests
a similar pathophysiological mechanism behind the proﬁ-
brotic function of C5a in liver disease and pancreatitis.
Activation of the complement system by pancreatic pro-
teases such as trypsin16,40 may start recovery from
pancreatic necrosis by induction of ﬁbrosis through acti-
vating PSCs.
Whether or not variants of the human C5 gene represent
risk factors for ﬁbrotic disease has been discussed contro-
versially. The SNPs rs17611 and rs2300929 have been
found to be associated with increased liver ﬁbrosis in a
small cohort reported by Hillebrandt et al,10 but the results
could not be replicated in a larger, multicenter conﬁrmation
study.12 We therefore investigated the allele distribution of
these C5 SNPs in a prospectively recruited cohort of
pancreatitis patients and found that none of these mutations
was associated with an increased risk for acute or chronic
pancreatitis when compared with healthy blood donors
from the same area. However, the formerly reported risk
alleles lead to increased transcription levels of C5 in a large
population-based cohort. In context to our animal studies
this observation indicated that previously reported riskalleles can predispose to higher circulating C5 levels and
thus a more ﬁbrogenic environment in pancreatitis.
Targeting PSCs and their proﬁbrotic mediators would be
a promising new therapeutic strategy to reduce ﬁbrogenesis
and disease progression in chronic pancreatitis. Previously,
Emori et al41 found that the serine protease inhibitor
camostat reduces ﬁbrogenesis in a rat model of chronic
pancreatitis, an effect that could be mediated via the com-
plement cascade. However, the use of broad-spectrum
serine protease inhibitors in chronic disease could be
burdened with a number of side effects. Our ﬁnding that
direct blockage of C5aR1 by a small-molecule inhibitor in a
therapeutic setting reduces the progression of chronic
pancreatitis suggests that pharmacologic inhibition of C5
may represent a valid therapeutic approach. Eculizumab, a
Food and Drug Administration–approved therapeutic anti-
body blocking C5 activation, could be a promising agent for
testing in randomized clinical trials.42
In conclusion, we have identiﬁed C5 in 2 models of
chronic pancreatitis as a drugable mediator of pancreatic
ﬁbrosis that directly activates pancreatic stellate cells and
whose deletion or inhibition greatly reduces ﬁbrogenesis
after pancreatic necrosis.Supplementary Material
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Supplementary Material and Methods
Materials
Cerulein was obtained from Sigma (Taufkirchen, Ger-
many). Human MPO was from Calbiochem (San Diego, CA).
The elastase substrate R110-(CBZ-Ala-Ala) was obtained
from Invitrogen (Eugene, OR). The Amyl amylase quantiﬁ-
cation kit as well as the Lip lipase quantiﬁcation kit were
purchased from RocheHitachi (Grenzach-Whylen, Germany).
Recombinant mouse TGFb1 was obtained from Cell Signaling
Technology (Danvers, MA) and recombinant mouse C5a was
obtained from Hyculttec (Beutelsbach, Germany). All other
chemicals of highest purity were obtained either from Sigma-
Aldrich (Eppelheim, Germany), Merck (Darmstadt, Germany),
Amersham Pharmacia Biotech (Buckinghamshire, UK), or
Bio-Rad (Hercules, CA). The C5a-receptor antagonist
(W-54011) was obtained from Calbiochem.1 Peptide inhibi-
tor for C5a receptor AcF-(OpdChaWR) as well as inactive
control peptide AcdChaPWFRO-NH2 characterized by
Kourtzelis et al,2 were synthesized by Biosyntan GmbH.
Animal Models
C57Bl6 mice were purchased from Charles River (Ger-
many), breeder pairs of C5-deﬁcient mice as well as C5
wild-type animals were purchased from Jackson Lab.3
Chronic pancreatitis was induced by ligation of the
pancreatic duct at the junction between the gastric and the
duodenal lobe, sparing the bile duct and its concomitant
artery in animals at the age of 8–10 weeks weighing
approximately 25 g (Figure 1A). The animals received a
single application of cerulein (50 mg/kg/body weight) 2
days after duct ligation. Animals were killed at 3, 7, 14, and
21 days after ligation. Inhibition of C5a receptor was per-
formed by daily IP injections of C5a-receptor antagonist
W-54011 (200 mg/kg/body weight) starting 4 days after
duct ligation. Peptide inhibitor as well as inactive control
peptide were injected daily intraperitoneally in a concen-
tration of 10 mmol/L starting on day 4 after ligation. Ani-
mals were killed 14 days after pancreatic duct ligation.
A second model of chronic pancreatitis was induced by 6
IP injections of cerulein (50 mg/kg/body weight) twice a
week over a time period of 10 weeks. The animals were killed
2 days after the last course of injection. Acute pancreatitis
was induced by 8-hourly IP injection of supramaximal con-
centrations of cerulein (50 mg/kg/body weight). All animals
were starved overnight with access to water ad libitum.
Open ﬁeld analysis for measurement of pancreatic pain
was performed in a 50  50 cm square box, as described by
Cattaruzza et al.4 Voluntary movement of mice was detected
by a camera and distances of movement were analyzed with
ImageJ software. All animal experiments were performed after
prior approval by the institutional animal care committee.
Histology, Immunohistochemistry, and
Immunoﬂuorescence
Pancreatic tissue, lung, and liver from killed animals
were ﬁxed immediately in 4% formalin for parafﬁn
embedding. Parafﬁn sections were used for H&E staining
and Masson–Goldner staining. Antigen retrieval of parafﬁn
sections for immunohistochemistry was performed with
Target Retrieval Solution (Dako). Fibrosis was detected by
collagen I staining (rabbit polyclonal, cat no. ab292;
Abcam), proliferation was assessed by nuclear localization
of Ki67 (rabbit polyclonal, cat no. IHC-00375; Bethyl), and
stellate cells were detected by aSMA staining (mouse
monoclonal clone 1A4; Sigma-Aldrich). Inﬁltrating macro-
phages were detected by anti–Mac-3 antibody (rat mono-
clonal, clone M3/84; BD Pharmingen), and differentiation
between M1 and M2 macrophages was performed by ﬂuo-
rescence labeling of the M1 population by CD68 (antibody
online, cat no. ABIN181836) and of the M2 population by
CD206 (antibody online, cat no. ABIN1386219) in cryo
sections of the pancreas. Neutrophils were labeled with
anti-MPO antibody (polyclonal rabbit, cat no. ab45977;
Abcam). Anti-protein gene product 9.5 (rabbit polyclonal,
ref. Z5116; Dako) was used to stain pancreatic nerves.
Intact b-cells were labeled with anti-insulin (4590; Cell
Signaling). Anti–cytokeratin 19 (polyclonal rabbit, cat no.
ab15463; Abcam) was used to label ductal structures. An-
tibodies were used in a dilution of 1:50 up to 1:1000 in
Aureon bovine serim (Wageningen, The Netherlands) al-
bumin or 20% fetal calf serum.
Oil red staining was generated by the Oil Red O Stain Kit
(IHC World), Masson–Goldner staining was performed with
the Masson–Goldner staining Kit (Merck, Darmstadt,
Germany). Quantiﬁcation of Goldner staining and immuno-
histochemistry was performed using ImageJ and expressed
as a percentage of area staining positive for collagen I, in-
sulin, and aSMA staining (Supplementary Figure 1).
Immunoﬂuorescence staining in cryosections of
pancreatic tissue was used to localize C5a receptor (CD88).
Sections were ﬁxed in ice-cold methanol/acetone. CD88
antibody (rat monoclonal, cat no. 135804; BioLegend) was
used in a dilution of 1:100 in Aureon bovine serum albumin.
Anti–a-amylase (sc-46657; Santa Cruz) was used to mark
intact secretory tissue.
For immunoﬂuorescence staining of PSCs, cells were
cultured on chamber slides, ﬁxed with 4% formalin, per-
meabilized with 0.1% Triton X, and blocked using 1%
bovine serum albumin. CD88 antibody (antibodies online,
rabbit polyclonal, cat no ABIN272007) and aSMA antibody
were used in 1:200 in 1% bovine serum albumin.
Biochemical Assays
Serum levels of amylase and lipase were measured by
photometric assay (Roche Hitachi). Puriﬁed enzymes
(Sigma) were used as standard. Elastase in feces was
determined by ﬂuorometric enzyme kinetic over 1 hour at
37C using rhodamine-110-CBZ-Ala-Ala(2) (Invitrogen,
Karlsruhe, Germany) as substrate dissolved in 100 mmol/L
Tris containing 5 mmol/L CaCl2 at pH 8.0. Feces were
resuspended in 500 mmol/L NaCl, 100 mmol/L CaCl2
charged with 0.1% Triton X-100, and sonicated. For mea-
surements of MPO, pancreatic tissue was homogenized on
ice in 20 mmol/L potassium phosphate buffer (pH 7.4) and
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centrifuged. The pellet was resuspended in 50 mmol/L
potassium phosphate buffer (pH 6.0) containing 0.5%
cetyltrimethylammoniumbromide. The suspension was
freeze-thawed in cycles, sonicated, and centrifuged at
20,000g. MPO activity was assayed in 50 mmol/L potassium
phosphate buffer (pH 6) containing 0.53 mmol/L O-dia-
nisidine and 0.15 mmol/L H2O2. The initial increase in
absorbance was measured at room temperature with a
Spectramax spectrophotometer (Molecular Devices, Biber-
ach, Germany). The results are expressed in units of MPO
activity. Cytokines were measured by ﬂuorescence-
activated cell sorter analysis with cytometric bead array
from Becton Dickinson (mouse inﬂammation kit, cat:
552364; Heidelberg, Germany).5
Western Blot Analysis
Tissue samples or plated PSCs for Western blot experi-
ments were homogenized on ice in lysis buffer containing 25
mmol/LHEPES (pH7.5), 75mmol/LNaCl, 0.5%Triton X-100,
5% glycerol, and 1 mmol/L EDTA in the presence of different
protease inhibitors (10 mmol/L NaF, 5 mmol/L Na4P2O7, 1
mmol/L phenylmethylsulfonyl ﬂuoride, and 1 mg/mL apro-
tinine). Protein contentwas determinedby theBradfordassay
or BCA kit from Pierce (Rockford, IL). In all, 10- to 50-mg
samples of total protein were loaded on 12.5% poly-
acrylamide gels and transferred to nitrocellulose membranes
for immunoblotting. aSMA antibody (Sigma Aldrich), CD88
antibody (Santa Cruz), and mouse anti-PCNA (Invitrogen,
Carlsbad, CA) were used at a dilution of 1:1000, anti-
–glyceraldehyde-3-phosphate dehydrogenase (mouse mono-
clonal, clone 6C5; Meridian, Memphis, TN) was used as
loading control. Densitometry for aSMAwas performed using
ImageJ software and dividing optical density of aSMA bands
by the optical density of the glyceraldehyde-3-phosphate de-
hydrogenase band after background subtraction.
Pancreatic Stellate Cell Isolation
Stellate cells were isolated from murine pancreas by
collagenase digestion and Nycodenz density gradient centri-
fugation (Nycomed Pharma, Oslo, Norway). This method was
established previously and described by Apte et al.6 The
pancreata of 4–5 mice were pooled to get enough cells for
the experimental setting. PSCs were maintained in Iscove’s
modiﬁed Dulbecco’s medium (Life Technologies, Grand
Island, NY) containing 10% heat-inactivated fetal calf serum
and PenStrep. Cells were used before the ﬁrst passage.
Polymerase Chain Reaction and Real-Time
Polymerase Chain Reaction Analysis of Isolated
Stellate Cells
Total RNA from PSCs was isolated using the RNeasy
mini kit and transcribed into complementary DNA using the
Quantitect RT kit from Qiagen (Hilden, Germany). Reagents
for regular polymerase chain reaction were from PAN
Biotech (Aidenbach, Germany). Real-time polymerase chain
reaction was conducted on a 7500 real-time polymerase
chain reaction system using Sybr Select Master Mix from
Life Technologies (Austin, TX). All primers were from
Invitrogen (Darmstadt, Germany): C5aR1: F-5’-ACTTCCTT
CAGAAGAGTTGCCT-3’, R-5’-AATGCCATCCGCAGGTATGT-3’;
aSMA: F-5’-GCCAGTCGCTGTCAGGAACCC-3’, R-5’-CCAGC
GAAGCCGGCCTTACA-3’; collagen I: F-5’-AGGCCACGCAT
GAGCCGAAG-3’, R-5-GCCATGCGTCAGGAGGGCAG-3’; col-
lagen 3: F-5’-AGGATCTGAGGGCTCGCCAGG-3’, R-5’-AGCCA
CCAGACTTTTCACCTCCA-3’; ﬁbronectin: F-5’-GCCTGAGG
TGGACCCCGCTA-3’, R-5’-GGGCCCAAGTGACCCGCATC-3’;
desmin: F-5’-TAGACGACCTGCAGAGGCT-3’, R-5’-GCGCTCCA
GGTCAATACGAG-3’; glyceraldehyde-3-phosphate dehydro-
genase: F-5’-CCCCAGCAAGGACACTGAGCAA-3’, R-5’-GTGGG
TGCAGCGAACTTTATTGATG-3’; laminin: F-5’-GGACGGGA
ATTCCGTTAGGG-3’, R-5’-TTGTAGGTCAAAGGCTCGGC-3’;
and Rpl32: F-5’-AACCCAGAGGCATTGACAAC-3’, R-5’-CACC
TCCAGCTCCTTGACAT-3’.
C5 SNP Analysis in Human Patients
With Pancreatitis
Blood samples frompatientswith pancreatitis admitted to
Greifswald University Medicine were collected after informed
consent and ethics committee approval7,8 and healthy blood
donors prospectively were collected, anonymized, and DNA
was isolated from leukocytes using samples centrifuged at
3000 rpm for 10 minutes. Genomic DNA was extracted from
the cell pellets using the DNA isolation kit I from Magna Pure
LC (initial cohort; Roche Diagnostics, Indianapolis, IN) or the
Quick-gDNA MiniPrep Kit (follow-up study; Zymo Research,
Irvine, CA). For SNP analysis only acute pancreatitis of a
nonbiliary and non–endoscopic retrograde chol-
angiopancreatography etiology, and for chronic disease only
alcohol-induced or idiopathic pancreatitis, were included.
TaqMan assays C_11720402_10 for the SNP rs17611 and
C_2783669_1 for SNP rs2300929 purchased from Life Tech-
nologies (Grand Island, NY) were used for genotyping. Taq-
Man products were veriﬁed by direct sequencing.
Expression of Quantitative Trait Loci
Analysis of Candidate SNPs
The Study of Health in Pomerania is a longitudinal
population-based cohort study in West Pomerania, a region
in northeast Germany, assessing the prevalence and inci-
dence of common population-relevant diseases and their
risk factors. Baseline examinations for the Study of Health in
Pomerania–TREND were performed between 2008 and
2012, comprising 4420 participants. Study design and
sampling methods were reported previously.9 The present
expression of quantitative trait loci analysis was based on a
subset of 976 subjects aged 20–81 years from the Study of
Health in Pomerania–TREND study population for which
genome-wide SNP typing data as well as genome-wide
whole-blood gene expression data were available.2,8
Statistical Analysis
All data are expressed as means ± SEM from at least 5
animals in each group. Statistical analyses were performed
using Sigma-Plot for the animal experiments and Prism
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(Statcon, Witzenhausen, Germany) for PSC experiments and
human data. An unpaired, 2-tailed, Student t test was used
for statistical analysis of in vivo and in vitro experiments
and the Fisher exact test was used for human C5 SNP
analysis. Differences were considered signiﬁcant at a level of
a P value less than .05.
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Supplementary Table 1.Allele Frequency of C5 SNPs rs17611 and rs 2300929 in Patients With Pancreatitis
Chronic pancreatitis Acute pancreatitis Blood donors
n % n % P n % P
rs17611
n 390 133 384
AA 84 21.5385 23 17.2932 76 19.7917
AG 183 46.9231 75 56.391 197 51.3021
GG 123 31.5385 35 26.3158 111 28.9063
A 351 45 121 45.4887 349 45.4427
G 429 55 145 54.5113 .9431 419 54.5573 .8783
rs2300929
n 390 133 384
TT 311 79.7436 104 78.1955 310 80.7292
TC 77 19.7436 27 20.3008 68 17.7083
CC 2 0.51282 2 1.50376 6 1.5625
T 699 89.6154 235 88.3459 688 89.5833
C 81 10.3846 31 11.6541 .5668 80 10.4167 1.0000
Supplementary Table 2.Demographic Data of Cohorts for
SNP Analysis
Chronic
pancreatitis
Acute
pancreatitis
Blood
donors
P P
Median age, y 45 47 .2802 33 <.0001
Female 24.17% 26.32% .5603 45.57% <.0001
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Supplementary Figure 1.Quantiﬁcation of ﬁbrosis by ImageJ software. ImageJ is used for the quantiﬁcation of ﬁbrosis from
Masson–Goldner trichrome staining or haematoxylin-3,30-diaminobenzidine (H-DAB) staining or a respective protein such as
aSMA or collagen I.
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Supplementary Figure 2. Pancreatic duct ligation without cerulein hyperstimulation and open ﬁeld analysis in animals with
chronic pancreatitis (CP). (A) Pancreatic duct ligation without supramaximal cerulein stimulation served as control for the
characterization of the model. In duct ligation alone we observed less extended areas of necrosis (H&E staining), less ﬁbrosis
(trichrome staining, collagen I), a less-pronounced inﬂammatory inﬁltrate, but atrophy of the gland over time. Morphometric
quantiﬁcation of ﬁbrosis on Masson–Goldner trichrome staining and collagen I shows a signiﬁcant increase in extracellular
matrix in duct-ligated, cerulein-stimulated animals compared with ligation without cerulein stimulations. Interestingly, open
ﬁeld analysis to measure pancreatic pain showed a signiﬁcant decrease in traveled distance in the duct ligation/hyperstim-
ulation model in comparison with repetitive cerulein application. (B) Voluntary movement and the distance traveled by animals
in the duct ligation/hyperstimulation. More than 5 animals were used for each experiment and all experiments were performed
in triplicate. All experiments were performed independently on 3 or more occasions. Asterisks indicate signiﬁcant differences
with a P value less than .05.
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Supplementary Figure 3. Direct comparison of the duct ligation/hyperstimulation model to repetitive supraphysiological
cerulein injections with regard to ﬁbrogenesis. (A and B) Morphometric quantiﬁcation of ﬁbrosis on Masson–Goldner trichrome
staining, collagen I, and aSMA staining showed a highly signiﬁcant difference of ﬁbrosis between the duct ligation model at
day 21 and after 10 weeks of repetitive cerulein stimulation. More than 5 animals were used for each experiment and all
experiments were performed in triplicate. All experiments were performed independently on 3 or more occasions. Asterisks
indicate signiﬁcant differences with a P value less than .05.
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Supplementary Figure 4. Further characterization of the duct ligation/hyperstimulation model in C57Bl6 mice. (A) H&E
staining of the lungs of animals with chronic pancreatitis upon concomitant duct ligation and supramaximal secretagogue
stimulation showed a strong systemic inﬂammatory reaction with thickening of the alveolar wall and hyperemia. H&E staining
of the liver showed extended areas of necrosis at 3 and 7 days after surgery, which resolved at later time points, ruling out
mechanical cholestasis as a confounding factor. Staining of cytokeratin 19 (CK19) illustrated strong expression of intact but
dilated pancreatic ducts over the time course of chronic pancreatitis. (B) Time course of serum lipase activity and IL6 serum
levels in chronic pancreatitis in the duct ligation model. (C) Staining of insulin over the time course of chronic pancreatitis in
mice showed unchanged numbers of insulin-producing cells and, after a dip in the early necrotizing disease phase, a pre-
served endocrine function in the duct-ligated mouse model. Quantiﬁcation of the M1 and M2 populations of macrophages
showed a predominance of the proinﬂammatory M1 macrophages in the early disease course, peaking at day 3 in pancreatic
tissue. (D) Thereafter, a steady increase in M2 macrophages, which are considered responsible for extracellular matrix
deposition in the later course of chronic pancreatitis, was observed. Asterisks indicate signiﬁcant differences with P < .05.
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Supplementary Figure 5. C5 in cerulein-induced pancreatitis. Acute pancreatitis was induced by supramaximal cerulein
administration (50 mg/kg/body weight) in C5þ/þ and C5-/- animals. (A) Serum amylase and lipase activity showed an increase
after induction of pancreatitis, but amylase and lipase activities were not found to be different between the 2 animal strains. (B)
Representation of H&E stainings at 0, 1, and 8 hours of repetitive cerulein IP injection in C5þ/þ compared with C5-/- animals;
0h represents untreated control. H&E staining of the pancreas showed an equal amount of inﬁltrating cells as well as equal
levels of tissue damage characterized by areas of necrosis or edema. (C) Myeloperoxidase activity in pancreatic tissue ho-
mogenate was found to be increased over time but did not differ between C5þ/þ and C5-/- animals. (D) Serum levels of the
proinﬂammatory cytokine IL6 or the chemokine monocyte chemoattractant protein (MCP)-1 were not different between C5þ/þ
and C5-/- mice. More than 5 animals were used for each experiment and all experiments were performed in triplicate. All
experiments were performed independently on 3 or more occasions. Asterisks indicate signiﬁcant differences with a P value
less than .05.
Supplementary Figure 6. Expression level of C5 in whole blood corresponding to the SNPs rs17611 and rs2300929. (A)
Shown are the residual (ie, after adjustment for technical effects and potential confounders, and overall mean-centered) mean
log2-transformed gene expression levels corresponding to gene-speciﬁc messenger RNA level in whole blood from a cis-
expression of quantitative trait loci analysis of 976 volunteers from the Study of Health in Pomerania–Trend cohort and 95%
conﬁdence intervals (y-axis) per genotype group (x-axis) of C5 adjusted for the ﬁrst 50 eigenvectors with respect to rs17611
and rs2300929 for SHIP–TREND. We detected a signiﬁcant association of rs17611_A with increased C5 expression measured
in whole blood with a P value of 6.87  10-41.
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Supplementary Figure 7. Full-length Western blot for C5a receptor on pancreatic cells. Western blots of different pancreatic
cells and tissues were preformed to analyze the expression of C5a receptor (CD88). The expected size of CD88 is approxi-
mately 49 kilodaltons. Isolated macrophages served as positive control. Freshly isolated PSCs (3 days of culture) show an
expression of CD88 in Western blot. Long-time culture of PSCs (6 days) leads to activation of cells and loss of CD88
expression. Duct cells, similar to isolated acinar cells, do not express CD88, in contrast to whole pancreatic tissue, which
shows a clear expression of CD88.
Supplementary Figure 8. Enlarged immunoﬂuorescent staining of C5a receptor (CD88) and aSMA shows expression of CD88
in different populations of cells but not in acinar cells. In addition, CD88/aSMA double-positive cells can be stained in chronic
pancreatitis tissue of mice, identifying them as PSCs.
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